Alkermes plc - Ordinary Shares (ALKS) Covered Calls

Alkermes plc is a fully integrated biopharmaceutical company that develops and commercializes innovative medicines designed to address unmet needs of patients with central nervous system diseases. The firm utilizes proprietary drug-delivery technologies to create novel treatments for conditions such as schizophrenia, bipolar I disorder, and alcohol and opioid dependence. Its diverse portfolio includes several leading proprietary commercial products.

You can sell covered calls on Alkermes plc - Ordinary Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for ALKS (prices last updated Fri 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Alkermes plc is a global biopharmaceutical leader dedicated to developing treatments for complex central nervous system (CNS) disorders. The company distinguishes itself through a dual-capability model, combining advanced medicinal chemistry with sophisticated pharmaceutical engineering. This approach has led to the creation of long-acting injectable therapies and oral medications that aim to improve patient adherence and clinical outcomes in mental health and addiction medicine.

Core Business and Therapeutics

The company's commercial portfolio is anchored by proprietary products designed for chronic management of severe mental illness and substance use disorders. Their long-acting injectables provide sustained medication release over weeks or months, reducing the daily burden of treatment for patients with schizophrenia. Additionally, the firm develops oral antipsychotics that incorporate metabolic modifiers to mitigate common side effects like weight gain. Beyond their own brands, the firm earns significant royalty revenue by licensing its drug-delivery technologies to other major pharmaceutical companies.

Competitive Landscape

The neuroscience market is highly competitive, with the company facing pressure from large-cap pharmaceutical firms and specialized biotech entities. Key competitors include:

1. Biogen: A pioneer in neuroscience that develops treatments for complex neurological and neurodegenerative diseases. They compete by offering a broad range of therapies for multiple sclerosis and other specialized CNS conditions.
2. Jazz Pharmaceuticals: A global biopharmaceutical company focused on developing medicines for sleep disorders and oncology. They compete in the neuroscience space through their established portfolio of treatments for narcolepsy and other sleep-related ailments.
3. Amgen: One of the world’s largest independent biotechnology companies with a vast array of therapeutic interests. They compete through significant R&D investments and a robust pipeline that often targets similar chronic disease states and medical niches.
4. Teva Pharmaceutical: A leader in both generic and specialty medicines, particularly in the CNS space. They compete by providing cost-effective alternatives as well as innovative branded therapies for movement disorders and schizophrenia.

Strategic Outlook and Innovation

The firm is currently focusing its research and development efforts on high-impact neuroscience programs, particularly those addressing cognitive impairment and mood disorders. Strategic initiatives include optimizing their commercial infrastructure to better serve healthcare providers in the mental health community. By leveraging its proprietary technologies to create next-generation formulations, the company seeks to maintain its leadership in long-acting therapies while exploring new biological pathways to treat some of the most challenging conditions in neuropsychiatry.

Want more examples? ALK Covered Calls | ALKT Covered Calls